Chinatsu Sakata-Sakurai

Chinatsu Sakata-Sakurai

Company: Astellas Pharma

Job title: Vice President, Primary Focus Lead, Targeted Protein Degradation,


Exploring Mechanisms of Action & Non-Canonical Approaches Against the RAS Pathway to Identify Promising Therapies 12:01 pm

The classic “undruggability” of RAS was overcome with the approval of Sotorasib, and now again with the approval of Adagrasib. The push for new RAS inhibitors has been followed by the emergence of many novel targeting approaches, such as degradation, protein modulation, and nanoparticles. Hence, it is vital to bring together various experts to examine…Read more

day: Workshop B

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.